ライフサイエンスコーパス: myeloperoxidase

1 is a selective and irreversible inhibitor of myeloperoxidase.

2 onships of the mammalian peroxidases LPO and myeloperoxidase.

3 and the previously undescribed cancer target myeloperoxidase.

4 cells with endogenous expression of CD20 or myeloperoxidase.

5 was the predominant protein associated with myeloperoxidase.

6 oantibodies directed against proteinase 3 or myeloperoxidase.

7 uding the ANCA autoantigens proteinase 3 and myeloperoxidase.

8 more commonly known targets proteinase 3 and myeloperoxidase.

9 hils and production of TNF-alpha, MIP-2, and myeloperoxidase.

10 serum bound dose-dependently to solid-phase myeloperoxidase.

11 cies that are generated by their heme enzyme myeloperoxidase.

12 illations, pancreatic amylase, and pulmonary myeloperoxidase.

13 oxygen metabolites by the NADPH oxidase and myeloperoxidase.

14 panel resulted in various levels of urinary myeloperoxidase.

15 significant for AAT (28.71; P < 0.0001) and myeloperoxidase (62.79; P < 0.0001) over a 3-mo lag and

16 Myeloperoxidase, a heme enzyme released by polymorphonuc

17 in myeloblasts and promyelocytes, similar to myeloperoxidase, a marker of azurophil granules.

18 nfiltration is a prerequisite for myocardial myeloperoxidase accumulation.

19 n also significantly decreased the increased myeloperoxidase activities and osteoclast and neutrophil

20 e determined by TUNEL, whereas caspase-3 and myeloperoxidase activities were assessed spectrophotomet

21 ion, neutrophil and osteoclast densities and myeloperoxidase activities were determined in gingival t

22 features, histological characteristics, and myeloperoxidase activities.

23 ophil infiltration (p = 0.04), and pulmonary myeloperoxidase activity (p = 0.026).

24 litic mice significantly reduced the colonic myeloperoxidase activity and alleviated proinflammatory

25 Gingival myeloperoxidase activity and gingival levels of interleu

26 Analysis of myeloperoxidase activity and Ly6G immunostaining showed

27 onylation was dependent on NADPH oxidase and myeloperoxidase activity and was inhibited by butylated

28 ity by scoring, joint function by grid test, myeloperoxidase activity by luminescence, vascular leaka

29 roscopic damage scores, bowel thickness, and myeloperoxidase activity compared with untreated animals

30 il numbers, neutrophil CD11b expression, and myeloperoxidase activity compared with wild-type litterm

31 sis factor-alpha and interleukin-1beta), and myeloperoxidase activity followed by Ly6-G positive cell

32 indicate that the ability of EGCG to inhibit myeloperoxidase activity is one of the mechanisms by whi

33 We show here that myeloperoxidase activity leads to elevated accumulation

34 Together these results support targeting myeloperoxidase activity to reduce genetic damage leadin

35 For both drugs, the effect of myeloperoxidase activity was greater for TOP2B than for

36 At 21 hours after resuscitation, pulmonary myeloperoxidase activity was higher in lambs resuscitate

37 production in the tibiotarsal joint, but not myeloperoxidase activity was significantly reduced by Sz

38 ocyte chemokines (KC, MCP-1, and RANTES) and myeloperoxidase activity were also significantly elevate

39 iments, lung protein leakage, cytokines, and myeloperoxidase activity were investigated.

40 Alveolar bone resorption and myeloperoxidase activity were statistically higher in th

41 k of albumin), lung neutrophil accumulation (myeloperoxidase activity), and neutrophils in bronchial

42 , neutrophils, lung neutrophil accumulation (myeloperoxidase activity), and proinflammatory cytokines

43 k of albumin), lung neutrophil accumulation (myeloperoxidase activity), total number of WBCs, and neu

44 related with reduced neutrophil recruitment, myeloperoxidase activity, and air space cytokine concent

45 ransferase, hepatic neutrophil activation by myeloperoxidase activity, and cytokine secretion at spec

46 nt, TxA induced robust intestinal secretion, myeloperoxidase activity, and histopathologic indication

47 of colonic inflammation (e.g., weight loss, myeloperoxidase activity, and Ikappabalpha accumulation)

48 ytic capacity, high peroxide production, low myeloperoxidase activity, and low cytoplasmic granule co

49 serum amylase activity, pathological scores, myeloperoxidase activity, and the expression of inflamma

50 se of bone alkaline phosphatase, decrease of myeloperoxidase activity, as well as significant reducti

51 ry hypertension and attenuated the pulmonary myeloperoxidase activity, as well as tissue injury and s

52 ed in aggravated airway neutrophilia, tissue myeloperoxidase activity, cytokine contents, and decreas

53 ng injuries were assessed by bacterial load, myeloperoxidase activity, endothelial permeability (pulm

54 Molecular mechanisms were evaluated by myeloperoxidase activity, gene expression of RAGE, and m

55 ung injury as evident by reduced lung edema, myeloperoxidase activity, histological lung injury score

56 with controls (based on loss of body weight, myeloperoxidase activity, inflammatory cytokine producti

57 inistration significantly inhibited gingival myeloperoxidase activity, interleukin (IL)-1beta, tumor

58 nflammatory cytokine concentrations in lung, myeloperoxidase activity, Ly6G immunohistochemistry, and

59 xpression of inflammatory markers, including myeloperoxidase activity, monocyte chemotactic protein-1

60 lence of S. pneumoniae, as well as host cell myeloperoxidase activity, proinflammatory cytokine secre

61 nd neutrophil/macrophage infiltration, lower myeloperoxidase activity, reduced oxidative injury and i

62 nfiltration of inflammatory cells, and renal myeloperoxidase activity.

63 IL-17A in colon along with increased colonic myeloperoxidase activity.

64 is, apoptosis staining, and determination of myeloperoxidase activity.

65 nse, with scarring characterized by stronger myeloperoxidase activity.

66 dates, leukocyte infiltration, and increased myeloperoxidase activity.

67 ol decreased diarrhea, body weight loss, and myeloperoxidase activity.

68 n Willebrand factor (VWF), thrombospondin-1, myeloperoxidase, ADAMTS-13, and active VWF (aVWF) were s

69 of environmental enteropathy (calprotectin, myeloperoxidase, alpha1-antitrypsin) and the prevalence

70 es were taken for plasma nitrite/nitrate and myeloperoxidase analyses.

71 Anti-myeloperoxidase ANCA was associated with HLA-DQ (P=2.1x1

72 proteinase 3 ANCA-associated vasculitis and myeloperoxidase ANCA-associated vasculitis are distinct

73 utoantibodies was similar in both those with myeloperoxidase-ANCA and proteinase 3-ANCA.

74 o positive for neutrophil myeloperoxidase in myeloperoxidase-ANCA-associated microscopic poliangiitis

75 Titers of anti-myeloperoxidase and anti-proteinase 3 antibodies were 15

76 ntibodies expressed high levels of perforin, myeloperoxidase and CCL5 mRNA.

77 Released extracellular DNA binds myeloperoxidase and citrullinated histone H4.

78 of neutrophil secretory proteins, including myeloperoxidase and elastase, are associated with tissue

79 Myeloperoxidase and eosinophil peroxidase are heme-conta

80 used to detect the halogenating activity of myeloperoxidase and eosinophil peroxidase by using APF.

81 ted the different substrate specificities of myeloperoxidase and eosinophil peroxidase regarding chlo

82 lts suggest that peroxidase enzymes, such as myeloperoxidase and eosinophil peroxidase, may play a fu

83 le of rapidly binding and internalizing both myeloperoxidase and eosinophil peroxidase.

84 t mast cells led to enhanced autoimmunity to myeloperoxidase and greater disease severity compared wi

85 rbonaceous nature of NCS broke down by human myeloperoxidase and horseradish peroxidase enzymes, reve

86 aling regulated the release of antibacterial myeloperoxidase and lactoferrin.

87 feature of mammalian peroxidases, including myeloperoxidase and lactoperoxidase (LPO) is the existen

88 We measured levels of myeloperoxidase and macrophage inflammatory protein 2 (C

89 Neutrophil-related enzymes such as myeloperoxidase and neutrophil elastase did not contribu

90 It has been documented that apoA-I, myeloperoxidase and paraoxonase 1 (PON1) form a complex

91 reactive oxygen species by NADPH oxidase and myeloperoxidase and to be mediated by FcgammaRIIIb.

92 s of patients contained increased numbers of myeloperoxidase(+) and CD68(+) cells compared with panst

93 in inflammation, such as C-reactive protein, myeloperoxidase, and alarmin S100-A9.

94 istry of aortic tissue (n = 50) for S100A12, myeloperoxidase, and caspase 3 was examined and S100A12-

95 NET-bound antimicrobial proteins, elastase, myeloperoxidase, and cathepsin G, in response to these s

96 We recently showed that PON1, myeloperoxidase, and HDL bind to one another in vivo for

97 y active neutrophil primary granule enzymes, myeloperoxidase, and human neutrophil elastase.

98 Neutrophil gelatinase-associated lipocalin, myeloperoxidase, and intracellular ROS levels were highe

99 on of antimicrobial reactive oxygen species, myeloperoxidase, and lactoferrin, as well as the inflamm

100 ristic histone proteins, elastase, lysozyme, myeloperoxidase, and metabolic enzymes.

101 s, double-stranded DNA, neutrophil elastase, myeloperoxidase, and myeloid-related protein 8/14 were i

102 of the biomarkers alpha-1-antitrypsin (AAT), myeloperoxidase, and neopterin.

103 e surface mobilization of azurophilic (CD63, myeloperoxidase, and neutrophil elastase) and specific (

104 patterns, and the presence of antibodies to myeloperoxidase (anti-MPO) or proteinase 3 (anti-PR3) wa

105 ong patients who had a positive test for the myeloperoxidase antineutrophil cytoplasmic antibody.

106 ve decreased intracellular and surface-bound myeloperoxidase, are less capable of killing phagocytose

107 macrophages, with corresponding increase of myeloperoxidase as well as chlorinated and nitrosylated

108 Most contained myeloperoxidase, as seen in NETs in other tissues, where

109 neutrophil (PMN) infiltration (determined by myeloperoxidase assay), and bacterial load, but it dimin

110 Lung sections were stained for the myeloperoxidase assay.

111 Multiplex cytokine and myeloperoxidase assays corroborated our finding that a s

112 for 4 weeks lead to significant increases in myeloperoxidase, asymmetrical dimethylarginine, and card

113 ting of high-sensitivity C-reactive protein, myeloperoxidase, B-type natriuretic peptide, soluble fms

114 results indicate that ceruloplasmin inhibits myeloperoxidase by reducing Compound I and then trapping

115 ine levels, histologic damage scores, tissue myeloperoxidase concentrations, and preserved AMP concen

116 orinated lipids are generated as a result of myeloperoxidase-containing leukocyte-derived hypochlorou

117 cell cycling, but negatively correlated with myeloperoxidase content in granulopoietic precursors.

118 decreased serum MDA and renal tissue MDA and myeloperoxidase contents.

119 to quantification of migrated neutrophils by myeloperoxidase correlation, a destructive assay that pr

120 here were significant differences in cardiac myeloperoxidase, cytokines, neutrophil, and macrophage i

121 Myeloperoxidase, D-dimer, and matrix metalloproteinase 9

122 ferent murine models of myocardial ischemia, myeloperoxidase deficiency profoundly decreased vulnerab

123 Ventricles from myeloperoxidase-deficient (Mpo(-/-)) mice showed less pr

124 vivo investigations linked Cx43 breakdown to myeloperoxidase-dependent activation of matrix metallopr

125 oxytoluene and Trolox, indicating a role for myeloperoxidase-dependent lipid peroxidation.

126 In contrast, plasma levels of myeloperoxidase did not differ between the groups.

127 munofluorescence microscopy, immunoblotting, myeloperoxidase-DNA complex ELISA, and flow cytometry.

128 ld against inadvertent oxidant production by myeloperoxidase during inflammation.

129 We present effects of myeloperoxidase elevating single nucleotide polymorphism

130 tinography, histology, bacterial counts, and myeloperoxidase ELISAs.

131 Myeloperoxidase emerges as a crucial mediator of postisc

132 To reveal the role of myeloperoxidase for the development of ventricular arrhy

133 ent of animals with APC abrogated release of myeloperoxidase from neutrophils, a marker of neutrophil

134 acids with prostate cancer risk, and whether myeloperoxidase G-463A (rs2333227) modified the associat

135 The enzyme myeloperoxidase generates significant amounts of hypochl

136 as incubated in vitro with nitrating nitrite/myeloperoxidase/glucose oxidase.

137 In contrast, upon treatment with myeloperoxidase, H2O2, and NaCl, the oxidized HiPco SWCN

138 3 to hypochlorous acid (HOCl), produced by a myeloperoxidase-H2O2-Cl(-) system, and determined its re

139 omyocytes, Cx43 protein content decreased on myeloperoxidase/H2O2 incubation.

140 Myeloperoxidase has a negative impact on HDL function, w

141 1 supports the hypothesis that inhibition of myeloperoxidase has an effect on microglia.

142 skin lesions that contained lower levels of myeloperoxidase, IL-17A, and CXCL1, compared with wild t

143 utrophils strongly correlated with BAL fluid myeloperoxidase, IL-8, IL-1alpha, IL-6, granulocyte colo

144 of the mouse ileum after allo-HCT by in vivo myeloperoxidase imaging and found that infiltration leve

145 Myeloperoxidase in conditioned media from neutrophils wa

146 dendritic cells also positive for neutrophil myeloperoxidase in myeloperoxidase-ANCA-associated micro

147 The halogenating activity of myeloperoxidase in neutrophils can be determined by the

148 ory biomarkers matrix metallopeptidase-9 and myeloperoxidase in plasma and sputum; ANC lower than 1.5

149 synovitis and bone erosion, as well as less myeloperoxidase in synovial tissue.

150 Myeloperoxidase in tears may be a sensitive and specific

151 e recipient was connected to lower levels of myeloperoxidase in the intestinal tract of mice developi

152 s of the chemokines MCP-1 and KC, as well as myeloperoxidase in the lungs of sickle cell mice treated

153 for a causal rather than bystander role for myeloperoxidase in the progression of cerebrovascular di

154 potently inhibit the proinflammatory enzyme myeloperoxidase in vitro in a dose-dependent manner over

155 n analysis of ischaemic stroke subtypes, the myeloperoxidase increasing genetic risk score was strong

156 orresponding to a one allele increase in the myeloperoxidase increasing genetic risk score.

157 -deficient (CD11b(-/-)) mice and intravenous myeloperoxidase infusion revealed that neutrophil infilt

158 loplasmin was a potent inhibitor of purified myeloperoxidase, inhibiting production of hypochlorous a

159 hese factors have led to the hypothesis that myeloperoxidase inhibition could protect hematopoietic c

160 his response was blocked by the irreversible myeloperoxidase inhibitor 4-amino-benzoic acid hydrazide

161 by the recent development of novel specific myeloperoxidase inhibitors for use in inflammatory disea

162 Myeloperoxidase is a neutrophil enzyme that promotes oxi

163 Myeloperoxidase is a reactive oxygen generating enzyme a

164 Myeloperoxidase is expressed exclusively in granulocytes

165 f the wound, as represented by expression of myeloperoxidase level, was also significantly higher in

166 rom prior genome-wide studies of circulating myeloperoxidase levels (P < 5 x 10-6).

167 Pulmonary myeloperoxidase levels and BAL levels of G-CSF and TFG-b

168 g that common genetic variants that increase myeloperoxidase levels increase risk of primary intracer

169 We hypothesized that genetic determinants of myeloperoxidase levels influence the development of vasc

170 A genetic risk score reflecting elevated myeloperoxidase levels was constructed from 15 common si

171 Genetic determinants of elevated circulating myeloperoxidase levels were associated with both primary

172 Myeloperoxidase levels were determined in gingival tissu

173 tion, histopathology, malondialdehyde (MDA), myeloperoxidase levels, and antioxidant enzyme expressio

174 alveolar space, decreased total protein and myeloperoxidase levels, and lower cytokine levels in the

175 Plasma N-terminal-proANP, myeloperoxidase, lipoprotein-associated phospholipase A2

176 After immunization with myeloperoxidase, mast cells migrated from the skin to th

177 Our observations indicate that myeloperoxidase may contribute to the generation of dysf

178 isocyanate derived from urea dissociation or myeloperoxidase-mediated catabolism of thiocyanate to fr

179 im was to determine the relationship between myeloperoxidase-mediated oxidative damage to apolipoprot

180 f distinct surface markers (CD106, CD162 and myeloperoxidase MPO) was analyzed.

181 oderm (PLPM) expression of neutrophil marker myeloperoxidase mpo/mpx.

182 ification based on ANCA with specificity for myeloperoxidase (MPO ANCA) versus ANCA with specificity

183 Severity of infection, bacterial recovery, myeloperoxidase (MPO) activity and percent loss of retin

184 The gingival tissue was used to quantify the myeloperoxidase (MPO) activity and tumor necrosis factor

185 serum bone alkaline phosphatase (B-ALP) and myeloperoxidase (MPO) activity in gingival tissues were

186 of transglutaminase factor XIII (FXIII) and myeloperoxidase (MPO) activity to monitor how monocyte s

187 rted the use of luminol for the detection of myeloperoxidase (MPO) activity using optical imaging in

188 al bleeding index (GBI), probing depth (PD), myeloperoxidase (MPO) activity, alveolar bone loss (ABL)

189 examining their pulmonary appearance, edema, myeloperoxidase (MPO) activity, and histopathology.

190 ic resonance (MR) imaging agent specific for myeloperoxidase (MPO) activity, could detect MPO activit

191 peroxidasin from other peroxidases, such as myeloperoxidase (MPO) and eosinophil peroxidase (EPO).

192 Neutrophil primary granule components, myeloperoxidase (MPO) and human neutrophil elastase (HNE

193 alcium, reactive oxygen species, the enzymes myeloperoxidase (MPO) and neutrophil elastase.

194 It also decreased the levels of H2O2, myeloperoxidase (MPO) and nitric oxide (NO) in serum and

195 Myeloperoxidase (MPO) and paraoxonase 1 (PON1) are high-

196 fic DNA methylation of the autoantigen genes myeloperoxidase (MPO) and proteinase 3 (PRTN3) in leukoc

197 The most common ANCA target antigens are myeloperoxidase (MPO) and proteinase 3.

198 olitis in mice by decreasing the activity of myeloperoxidase (MPO) and the expression of pro-inflamma

199 es and their derivatives would abrogate anti-myeloperoxidase (MPO) antibody-induced NCGN in a mouse m

200 We used a mouse model of anti-myeloperoxidase (MPO) antibody-induced NCGN to determine

201 Increased systemic levels of myeloperoxidase (MPO) are associated with the risk of co

202 Proteinase 3 (PR3) and myeloperoxidase (MPO) are two major autoantigens in pati

203 The myeloperoxidase (MPO) assay was used to quantitate neutr

204 Neutrophil myeloperoxidase (MPO) can disrupt normal EC function, al

205 ive molecular imaging technologies targeting myeloperoxidase (MPO) can reveal early inflammation asso

206 Neutrophil myeloperoxidase (MPO) catalyzes the H2O2-dependent oxida

207 Oxidants derived from myeloperoxidase (MPO) contribute to inflammatory disease

208 The pathogenesis of acquired myeloperoxidase (MPO) deficiency, a rare phenomenon obse

209 elevated levels of DNA-histone complexes and myeloperoxidase (MPO) from neutrophil granules as well a

210 Oxidative damage by myeloperoxidase (MPO) has been proposed to deprive HDL o

211 n amperometric immunosensor for detection of myeloperoxidase (MPO) in human plasma is reported.

212 (NE), matrix metalloproteinases (MMPs), and myeloperoxidase (MPO) in tear washes of patients with oc

213 stric lesion area and also reduced levels of myeloperoxidase (MPO) in the gastric mucosa.

214 Myeloperoxidase (MPO) is a circulating cardiovascular di

215 Myeloperoxidase (MPO) is a heme peroxidase that catalyze

216 Myeloperoxidase (MPO) is a major player of the innate im

217 Myeloperoxidase (MPO) is a target antigen for antineutro

218 Myeloperoxidase (MPO) is a well defined autoantigen in A

219 Myeloperoxidase (MPO) is important in intracellular micr

220 Myeloperoxidase (MPO) is released during polymorphonucle

221 Myeloperoxidase (MPO) is synthesized by neutrophil and m

222 Western blots shows significant changes in Myeloperoxidase (MPO) level went down by 10%.

223 knockdown reduced brain edema and decreased myeloperoxidase (MPO) levels at 24 hours, and improved n

224 The heme enzyme myeloperoxidase (MPO) participates in innate immune defe

225 oxidants including hypochlorous acid, human myeloperoxidase (MPO) plays a critical role in innate im

226 The neutrophil enzyme myeloperoxidase (MPO) promotes oxidative stress in numer

227 Additionally, Scl-1 interferes with myeloperoxidase (MPO) release, a prerequisite for NET pr

228 Likely, myeloperoxidase (MPO) secreted by activated macrophages

229 Loss of tolerance to neutrophil myeloperoxidase (MPO) underlies the development of ANCA-

230 eleased by E. coli, is a potent inhibitor of myeloperoxidase (MPO), a bactericidal enzyme of the host

231 concept, the device has been used to detect myeloperoxidase (MPO), a cardiovascular biomarker.

232 Activation of myeloperoxidase (MPO), a heme protein primarily expresse

233 Blockade or genetic deletion of myeloperoxidase (MPO), a key neutrophil enzyme, signific

234 n that specifically binds and inhibits human myeloperoxidase (MPO), a major player in the oxidative d

235 Myeloperoxidase (MPO), a neutrophil and macrophage produ

236 m of the heavy chain component of the enzyme myeloperoxidase (MPO), a well-known lysosomal peroxidase

237 -8, MMP-9, tissue inhibitor of MMP (TIMP)-1, myeloperoxidase (MPO), and neutrophil elastase (NE) in p

238 leptin and resistin, the inflammatory marker myeloperoxidase (MPO), and the cytokine receptor for nuc

239 ilic granules of human neutrophils including myeloperoxidase (MPO), azurocidin, and neutrophil elasta

240 A potent oxidizing enzyme of neutrophils, myeloperoxidase (MPO), can effectively open the corked N

241 resonance (MR) imaging probe for the enzyme myeloperoxidase (MPO), might be a more sensitive contras

242 and serum matrix metalloproteinase (MMP)-9, myeloperoxidase (MPO), neutrophil elastase (NE), and MMP

243 peroxidase enzymes lactoperoxidase (LPO) and myeloperoxidase (MPO), nicotinamide adenine dinucleotide

244 NP), growth differentiation factor (GDF)-15, myeloperoxidase (MPO), placental growth factor (PlGF), s

245 nzyme-linked immunosorbent assay analysis of myeloperoxidase (MPO), tumor necrosis factor (TNF)-alpha

246 Specifically, myeloperoxidase (MPO), which is abundantly expressed in

247 measurements of the highly oxidative enzyme myeloperoxidase (MPO), which is implicated in many disea

248 sitive for either proteinase 3 (PR3)-ANCA or myeloperoxidase (MPO)-ANCA, were included in our study,

249 ss toxic treatment options for patients with myeloperoxidase (MPO)-ANCA-associated GN are needed.

250 Observations in experimental murine myeloperoxidase (MPO)-ANCA-associated vasculitis (AAV) s

251 body, is an indispensable constituent of the myeloperoxidase (MPO)-H2 O2 -halide system that produces

252 interleukin (IL)-1beta, IL-6, TNF-alpha, and myeloperoxidase (MPO).

253 enzymes (PAD4), neutrophil elastase (NE) and myeloperoxidase (MPO).

254 s are directed against proteinase 3 (PR3) or myeloperoxidase (MPO).

255 -sensitivity C-reactive protein (hs-CRP) and myeloperoxidase (MPO).

256 ysfunctional and are extensively oxidized by myeloperoxidase (MPO).

257 hich it inhibits the enzymatic activities of myeloperoxidase (MPO).

258 r-Kyoto (WKY) rats were immunised with human myeloperoxidase (MPO).

259 Fatty-acid binding proteins (FABP) and myeloperoxidases (MPO) are associated with many chronic

260 The release of granule proteases, such as myeloperoxidase, neutrophil elastase, and matrix metallo

261 en the 5th and 95th percentile (0.25) was by myeloperoxidase over a 2-mo lag.Of the 3 fecal biomarker

262 We found that myeloperoxidase oxidized 75% of the ascorbate in plasma

263 se (p < 0.001), proteinase-3 (p < 0.01), and myeloperoxidase (p < 0.001).

264 e and lacunar stroke, directly implicate the myeloperoxidase pathway in the pathogenesis of cerebral

265 pport of our experimental findings, baseline myeloperoxidase plasma levels were independently associa

266 ial dysfunction (matrix metalloproteinase-9, myeloperoxidase, plasminogen activator inhibitor-1, solu

267 Myeloperoxidase plays a central role in initiation and p

268 Treatment with 25 nm myeloperoxidase plus 50 mum H2O2 reduced ADAMTS13 activi

269 vps45 deficiency showed a marked paucity of myeloperoxidase-positive cells (i.e., neutrophils).

270 ge range, 4-76 years) was mainly composed of myeloperoxidase-positive immature myelomonocytic cells w

271 del of ischemia, the post-ischemic influx of myeloperoxidase-positive neutrophils and CD14(+) monocyt

272 infection-related changes in lung histology, myeloperoxidase production, and lung weight.

273 c factor, cortisol, epidermal growth factor, myeloperoxidase, prolactin, resistin and soluble tumor n

274 Higher MBG was associated with higher myeloperoxidase (r=0.42, P<0.0001), B-type natriuretic p

275 species (IC50 in the range 22.4-40.6muM) and myeloperoxidase release (IC50 in the range 22.2-32.2muM)

276 dothelial oxidative and inflammatory events, myeloperoxidase release from neutrophils and its impact

277 neutrophil extracellular trap formation and myeloperoxidase release.

278 he mammalian peroxidases lactoperoxidase and myeloperoxidase revealed the presence of novel bacterial

279 AAT and myeloperoxidase seemed to interact strongly with age, wi

280 -mediated apoptosis-suppressing signals from myeloperoxidase, serum amyloid A, and bacterial DNA, shi

281 s diagnosed in some cases by the presence of myeloperoxidase-specific antibodies (MPO-ANCA).

282 against RNA, neutrophil cytoplasmic Ags, and myeloperoxidase than do TMPD-injected wild-type BALB/c m

283 ed airway neutrophilia and concentrations of myeloperoxidase than GSTM1-null patients.

284 d hydrogen peroxide, ceruloplasmin converted myeloperoxidase to Compound II and slowed its conversion

285 tates to hydrogen peroxide, which is used by myeloperoxidase to generate other oxidants, including th

286 ed back the dramatic reduction in neutrophil myeloperoxidase to the myeloid progenitors showing down-

287 Compound I, the Fe(V) redox intermediate of myeloperoxidase, to Compound II, which has Fe(IV) in its

288 it induced significantly elevated levels of myeloperoxidase, tumor necrosis factor, monocyte chemoat

289 No significant alterations in the levels of myeloperoxidase, VEGF, and collagen were noted.

290 tratracheal instillation of carrageenan plus myeloperoxidase via facilitating neutrophil apoptosis an

291 When myeloperoxidase was added to human plasma it became boun

292 Ex vivo, myeloperoxidase was demonstrated to induce fibroblast-to

293 mic inflammation during atherogenesis, human myeloperoxidase was incubated with glycine, H2O2, malond

294 Here, by quantifying extracellular DNA or myeloperoxidase, we demonstrate that APC binds human leu

295 (zonula occludens 1), and neutrophil influx (myeloperoxidase) were assessed using immunohistochemistr

296 Gly domain-containing linker protein 2, and myeloperoxidase) were differentially regulated in monocy

297 that related to intestinal function-AAT and myeloperoxidase-were associated with small but highly st

298 active protein, interleukin-receptor 1A, and myeloperoxidase, whereas MR-pro-ADM levels correlated wi

299 thione peroxidase, serum catalase, and colon myeloperoxidase while decreasing total fecal short-chain

300 ular inflammation, but prior studies linking myeloperoxidase with stroke risk have been inconclusive.